• About us
  • Science and Pipeline
  • Investors
  • Contact us
  • Home
  • About us
  • Science and Pipeline
  • Investors
  • Contact us

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 14, 2024 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – November 14, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company exploring new pathways towards a cancer-free future by using its INTASYL® siRNA gene silencing...

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Nov 7, 2024 | Press Releases

Presenting new clinical data from Phio’s on-going Phase 1b trialMarlborough, Massachusetts–(Newsfile Corp. – November 7, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a...

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Nov 1, 2024 | Press Releases

Registration Link for Presentation and live Q&A to take place, Thursday, November 7 at 12:00 pm ESTMarlborough Massachusetts–(Newsfile Corp. – November 1, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company...

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 24, 2024 | Press Releases

New clinical data from Phio’s on-going Phase 1b trial to be presentedMarlborough, Massachusetts–(Newsfile Corp. – October 24, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...

Correction to Registration Link to Access Phio Pharmaceuticals’ Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Oct 18, 2024 | Press Releases

Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDTMarlborough, Massachusetts–(Newsfile Corp. – October 18, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

Oct 18, 2024 | Press Releases

Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDT Marlborough, Massachusetts–(Newsfile Corp. – October 18, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
« Older Entries
Next Entries »

Recent Posts

  • Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial
  • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
  • Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort
  • Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894
  • Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Recent Comments

No comments to show.
Email Alerts

Stay up to date on news and investor alerts

Sign up now

© 2025 Phio Pharmaceuticals

  • Follow
  • Follow
  • Home
  • About us
  • Science and Pipeline
  • Investors
  • Contact us